Author: CannabisNewsWire (CNW)

About CannabisNewsWire CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge. To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CannabisNewsWire.com Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

India Globalization Capital Inc. (NYSE American: IGC) Leads the Way Forward with Revolutionary Cannabis-Based Treatment for Alzheimer’s Symptoms

  • Company’s investigational drug is being tested for the first time ever on humans in an FDA-approved study
  • In phase 1 studies, IGC-AD1 shows potential to safely reduce debilitating symptoms
  • IGC is actively building a portfolio of both cannabis-based and manufactured molecules that can address multiple areas of unmet medical needs

In groundbreaking work that establishes its commitment to being a pioneer in the treatment of Alzheimer’s disease, India Globalization Capital (NYSE American: IGC) is developing a cannabis-based investigational drug that is being tested for the first time ever on humans in an FDA-approved study (https://cnw.fm/6qps2). The company is developing its proprietary treatment, IGC-AD1, hoping to provide relief to the 55 million people worldwide struggling with agitation in dementia that results from Alzheimer’s.

IGC is focused on revolutionizing the treatment of Alzheimer’s with its game-changing treatment. In phase 1 studies, IGC-AD1 shows potential to safely reduce the debilitating symptoms that impact millions of Alzheimer’s patients and their caregivers. Featuring a low dose of THC, the treatment is the first natural cannabis-based investigational drug being tested in human FDA trials to treat Alzheimer’s patients; it provides medical benefits without psychoactive effects. “As millions of Alzheimer’s patients continue to suffer from agitation, anxiety, and depression, phase 2 clinical trials bring hope for a treatment,” the company reports.

In addition to IGC-AD1, IGC is actively building a portfolio of both cannabis-based and manufactured molecules that can address multiple areas of unmet medical needs (https://cnw.fm/67wqT). The company’s TGR-63 product is being studied for its potential to decrease Alzheimer’s markers, including plaque buildup, while also decreasing cognitive decline and improving memory. The company also has undisclosed molecules involved in exploratory activities.

With no current FDA-approved drugs to treat in Alzheimer’s patients, the company clearly has found a place where it can establish a foothold. In fact, last year less than 7% of drugs in clinical trials were focused on treating neuropsychiatric symptoms of Alzheimer’s. The time has clearly come for IGC. “What we do is important,” the company states. “With no known cure, our formulations have the potential to change lives.”

IGC develops advanced cannabinoid-based formulations for treating diseases, including but not limited to Alzheimer’s disease, Parkinson’s disease, chronic pain, and even pet seizures. The company sells various brands of CBD-based consumer products, including Holief, which includes gummies and pain relief creams for women experiencing premenstrual syndrome and dysmenorrhea (period cramps), and Sunday Seltzer, which includes a CBD-infused energy beverage. The company operates facilities in the United States under Good Manufacturing Practices.

For more information, visit the company’s website at www.IGCPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to IGC are available in the company’s newsroom at https://ibn.fm/IGC

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — Arizona Records $1.4B in Cannabis Sales in 2022

The total marijuana sales in Arizona in 2022 were similar to those in 2021, the first year the drug was legal for adult use, but the routes by which each year’s sales reached $1.4 billion were remarkably different. In 2021, medical cannabis sales accounted for $760 million, or nearly 55% of total sales. In 2022, recreational marijuana took the lead, accounting for roughly 70% of total sales, totaling more than $950 million. The medical cannabis market has dropped to just over $500 million.

Recreational cannabis sales ended 2022 with its best monthly total in December, totaling about $86.6 million, a small increase from the $85.8 million in the previous month. The monthly sales of medical marijuana remained stable, falling from $31.9 to $31.1 between November 2022 and December 2022.

Since the beginning of the legalization of adult-use in January 2021, cannabis sales have totaled $2.9 billion in both markets. Since April 2021, medical sales have decreased almost every month, with a few exceptions, such as July, when sales reached $71.6 million following a $5 million decline in June.

Patients continue to swarm to the recreational market, and producers of edibles and other ingestible products with higher potencies for medical use have started to cater to this market. The first full month of licensed recreational sales, February 2021, saw the lowest total sales for adult-use at around $40 million.

Medical marijuana patients pay about 6% in tax, while the state collects an additional 16% excise tax on recreational purchases in addition to the regular sales tax. Local governments add about 2% of the taxes. December saw a total of almost $23 million in tax collections.

A third of the taxes collected from recreational sales are committed to community colleges, with 25% earmarked for the Highway User Revenue Fund, another one-third to public safety — fire departments, police, and first responders — and 10% to the Justice Reinvestment Fund, which is committed to providing counseling services, job training, public health, and other social services for marginalized groups adversely affected by cannabis criminalization and arrests.

The monthly reports on the medical program are typically published one month prior by the state’s health services department (ADHS), which is responsible for the state’s cannabis regulation, before the reports from the revenue department.

As of January, there were 153,845 cardholders overall, with 128,621 of them being eligible patients. According to ADHS, those figures decreased by about 1,200 in December 2022, to 155,682 and 129,836, respectively. The state’s cardholders are divided into five groups: qualified patients, dispensary agents, designated caregivers, lab agents, and facility agents.

Those figures contrast sharply with the situation with medical marijuana at the start of 2021, when recreational sales started.

At that time, 309,479 people had medical cards, according to data from ADHS in January 2021. The number of qualified patients and dispensary agents was 299,054 and 9,489, respectively.

In terms of the quantities sold in January, the weight stood at 5,435 pounds, with flower at 4,645 pounds, and the rest accounted for other forms such as edibles.

As these marijuana sales figures climb, there is likely to be a commensurate increase in the use of cultivation equipment such as that sold by Advanced Container Technologies Inc. (OTC: ACTX), given that rising sales point to an increase in the produce being cultivated and processed.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — California’s Yearly Marijuana Sales Decline for First Time Since Launch of Recreational Market

New data from the California Department of Tax and Fee Administration shows that annual marijuana sales in the state dropped in 2022.  This is the first time since the state launched its recreational market five years ago that sales have fallen.

Last year, retailers raked in $5.3 billion in taxable sales of medical and recreational cannabis. This is quite a drop, in comparison to the $5.8 billion generated in 2021. Taxable sales in the fourth quarter also declined to $1.3 billion, down by almost 12% from the same period in 2021.

Hirsh Jain, Ananda Strategy’s founder, stated that the continued lack of retail outlets in various regions in the state along with low wholesale prices were the main drivers of this trend. Low wholesale prices make marijuana products cheaper for consumers. Ananda Strategy is a consultancy that advises leading marijuana retailers, brands and venture capital funds.

The marijuana industry consultant further observed that the state’s dual-licensing system had also made it harder for new dispensaries to launch since the recreational use of marijuana was permitted. Jain noted that this had limited the size of California’s legal marijuana market, causing it to plateau prematurely and regress.

California was the first state in the country to legalize the medical use of marijuana, after voters approved in the Compassionate Use Act in 1996.

Under California’s law, marijuana enterprises must acquire local authorization from the county/city they operate in before they can submit their application for a state license. This has caused delays in license issuance, which is affecting operators in different parts of the state, including Mendocino County.

In a letter penned earlier this month to Governor Gavin Newsom of California and Director Nicole Elliott of the Department of Cannabis Control, the Mendocino Cannabis Alliance called for regulators to step in as local governments hadn’t succeeded in establishing a process that could move good-faith marijuana operators towards annual licensure in the state.

California’s illegal market may have also affected sales at licensed retailers, a trend which emerged in the years before voters in the state legalized adult-use sales and possession in November 2016. Industry players estimate that the illicit market is twice the size of the regulated marijuana industry.

Marijuana businesses in the state also brought in roughly $1.1 billion in taxes last year, a more than 20% drop from 2021’s $1.4 billion. Experts believe the decrease partly arose from the scrapping of California’s cultivation tax, as well as the aforementioned regulatory and economic challenges.

It would be interesting to look into how this decline in cannabis sales in California is impacting companies such as REZYFi Inc. which specialize in funding marijuana companies in different jurisdictions.

NOTE TO INVESTORS: The latest news and updates relating to REZYFi Inc. are available in the company’s newsroom at https://cnw.fm/REZY

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – REZYFi Inc. Using Diversified Approach to Capitalize on Growth in Multiple Verticals

REZYFi, which is positioned as one of the first cannabis mortgage bankers in the United States, is servicing the needs of both traditional and non-traditional consumers and businesses. “The company targets markets that include licensed and permitted cannabis companies, owners of real estate who lease to cannabis companies, and companies and individuals seeking a variety of real estate-related first and additional mortgage-based financing and project-specific financings. Headquartered in Miami, Florida, REZYFi operates through two wholly owned subsidiaries – REZYFi Lending and ResMac Inc.,” a recent article reads. “Through REZYFi Lending, the company leverages a wide network to offer options such as 15- and 30-year fixed-rate loans, FHA and VA loans, reverse mortgages, jumbo loans, and adjustable-rate mortgages… REZYFi’s second wholly-owned subsidiary, ResMac, has been operating for 13 years. It has closed more than 20,000 loans for more than 15,000 clients. The company expects to accumulate $285 million in retail origination in 2023, alongside $250 million in wholesale origination for the same period. ResMac is further targeting $600 million in origination through its mortgage correspondent operation for 2023. REZYFi’s diversified approach to the real estate lending sector positions it to capitalize on growth in multiple verticals.”

To view the full article, visit https://cnw.fm/KT2gQ

About REZYFi Inc.

REZYFi is a cannabis-focused mortgage origination and specialized financing company in the U.S. The company originates, structures and invests in first mortgage loans and alternative structured financings secured by commercial and residential real estate properties. For more information, visit the company’s website at REZYFi.com.

NOTE TO INVESTORS: The latest news and updates relating to REZYFi are available in the company’s newsroom at https://cnw.fm/REZY

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Encouraging Results from DehydraTECH-CBD Diabetes Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that its diabetes animal model study DIAB-A22-1 has completed and produced at least three positive outcomes including weight loss in obese diabetic-conditioned animals, together with improved triglyceride and cholesterol levels. According to the update, the study evidenced, at times, dramatic changes in body weight, general activity and triglyceride and cholesterol levels associated with administration of DehydraTECH-CBD. The findings align well with other study work in animals that points to the known anti-inflammatory and antioxidant properties of CBD functioning to lessen some of the essential pathophysiological factors associated with diabetes. Pleased that relatively low doses of DehydraTECH-CBD seem to support real improvements in the day-to-day health of the lab animals, Lexaria is encouraged by the positive findings from its first study of DehydraTECH-CBD in this diabetes animal model. The findings indicate many prospective benefits worthy of further investigation, perhaps together with other drugs that further help to control glucose levels directly.

To view the full press release, visit https://cnw.fm/1ihUn

About Lexaria Bioscience Corp.

Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 28 patents granted and many patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Sugarmade Inc. (SGMD) Names New Board, Audit Committee Member

Sugarmade (OTC: SGMD), a product and branding marketing company investing in operations and technologies with disruptive potential, has appointed Darren Kenney as a new independent director and audit committee member. In the announcement, Sugarmade noted that it is focusing on an aggressive growth strategy and is looking to Kenney and his expertise to ensure the accuracy and integrity of company financial affair. An experienced CPA and licensed real estate broker in California, Kenney has built and sold three accounting practices over the past three decade; he has also served as a consultant with GTE (now Verizon), Saks Fifth Avenue and CalTrans. “This is another important step toward fulfilling the uplisting requirements to advance Sugarmade onto the OTCQB exchange as well as an essential factor in expanding our accounting and reporting capabilities as we pursue new acquisitions and prepare for a future uplisting onto the NASDAQ exchange,” said Sugarmade CEO Jimmy Chan in the press release.

To view the full press release, visit https://cnw.fm/LaOrY

About Sugarmade Inc.

Sugarmade is a product and branding marketing company investing in operations and technologies with disruptive potential. The company’s brand portfolio includes CarryOutsupplies.com, SugarRush(TM), J Grade Farm and Lemon Glow. For more information about the company, please visit www.Sugarmade.com.

NOTE TO INVESTORS: The latest news and updates relating to SGMD are available in the company’s newsroom at http://cnw.fm/SUGAR

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Uses Patented DehydraTECH(TM) Technology to Disrupt Drug Delivery Through Innovation

  • Lexaria’s DehydraTECH(TM) technology has 28 granted patents, with many more patents pending worldwide
  • DehydraTECH(TM) uses a patented formulation and dehydration process method to change how the body detects and absorbs drugs
  • Lexaria is focusing on three main areas: CBD for hypertension, oral nicotine to replace vaping and smoking, and CBD potentially for diabetes and seizures
  • Lexaria is conducting early work to support its FDA-registered IND program to investigate DehydraTECH(TM)-processed CBD for hypertension

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is increasing the bioavailability and improving the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through its patented proprietary technology, DehydraTECH(TM). DehydraTECH is applied to multiple ingestible product formats, such as tablets, capsules, oral suspensions, mouth melts, and others, with opportunities for success in cannabinoids, nicotine, antivirals, and other APIs. To date, Lexaria has 28 granted patents, with many more patents pending worldwide.

Lexaria’s DehydraTECH uses a patented formulation and dehydration processing method that changes how the body detects and absorbs drugs. The DehydraTECH process is beneficial to the end user because it speeds up onset, increases bioavailability, improves drug potency, eliminates the need for sugar-filled edibles, lowers dosage, and lowers administration costs.

In 2023, the company is focused on three main areas: cannabidiol (“CBD”) for hypertension, oral nicotine to replace vaping and smoking, and other applications for DehydraTECH-CBD such as diabetes and seizures. Lexaria has yielded several studies that have proven beneficial for its research and development efforts, including five human clinical trials completed involving DehydraTECH-CBD.

HYPER-H21-4 consisted of male and female volunteers between the ages of 40-70 with documented or measured elevated blood pressure. Participants received DehydraTECH-CBD every day for a 5-week duration, with doses escalating between 225 mg/day to 450 mg/day over the course of the study, adjusted relative to body weight. Some participants were already using the industry standard of care for hypertension, allowing Lexaria to study the efficacy and safety of DehydraTECH-CBD with and without other hypertension treatments. The extended duration of the study allowed Lexaria to gather critical data to evaluate the potential for long-term health benefits of its DehydraTECH-CBD formulation.

“Given that these were the primary objectives of the study, it is accurate to say that HYPER-H21-4 was a success,” Lexaria CEO Chris Bunka said in his annual letter to shareholders recently (https://cnw.fm/fXTep). “In addition, a series of secondary study objective evaluations, as previously announced, are in progress, and these findings will be released in due course if any of them are notable.”

Lexaria expects to launch its FDA-registered IND program to investigate DehydraTECH-CBD for hypertension formally. The program is a large undertaking, one that will dominate the second half of 2023 and beyond – the company expects to conduct fewer additional smaller studies than they have in years past due to the focus required for this study. Preparatory work for this Phase 1b study is well underway.

“We continue to enjoy more successes than failures. We’re hopeful that our commercial endeavors might obviate any need to raise capital via equity issuance at current market levels, and our tight fiscal controls have greatly assisted in that pursuit,” Bunka also said. He added that the company will explore various commercial arrangements in 2023 in order to increase cash flow, while also continuing efforts to build and enhance its client base.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — Research Finds Cannabis Users Have Lower Blood Pressure

Over the past decade or so, a growing body of research has revealed that cannabis has significant therapeutic potential. Studies have found that cannabis can be effective against a host of medical conditions, including chronic pain, insomnia and anxiety, with none of the side effects typically observed with pharmaceutical use.

Even as dozens of American states and overseas territories now allow their residents to purchase and use cannabis for medical purposes, researchers across the world are still trying to understand the plant’s full therapeutic potential. A recent study published in “NatureScientific Reports” journal has provided evidence linking cannabis usage to lower blood pressure.

For their study, investigators conducted an analysis of data gathered from more than 91,000 subjects to assess the relationship between blood pressure and marijuana consumption. They found that current and lifetime users of the plant tend to have lower blood pressure levels and that the effect was more pronounced in women compared to men.

Alexandre Vallée, the study’s lead researcher, highlighted that past studies on the relationship between blood pressure and cannabis use relied on a limited population pool and rarely looked at how cannabis consumption affected the blood pressure of different genders. This time, Vallée and her team sourced data from the UK Biobank, where a whopping 156,959 volunteers provided information on their cannabis use and blood pressure.

The researchers excluded 65,798 individuals who had past cardiovascular events and currently used antidepressants and antihypertensive drugs. They then the measured diastolic and systolic blood pressures of the remaining participants two times and asked them to report their lifetime cannabis use habits via a questionnaire.

Those who admitted to using cannabis a long time ago were still classified as marijuana users while participants who had never used the drugs were used as study controls. The cannabis users were then separated into other groups, based on their level of cannabis use and also whether they were former or current users.

According to the study, heavy lifetime cannabis use was linked to a reduction on both diastolic blood pressure and systolic blood pressure in both genders. Furthermore, the decrease in blood pressure was more pronounced in women compared to men. The researchers also observed that current cannabis users of both genders also exhibited lower blood pressure levels.

However, they noted that while other studies had also shown a stronger relationship between cannabis use and systolic pressure compared to cannabis use and diastolic pressure, they still weren’t completely certain of the relationship between cannabis and blood pressure. In their report, the investigators added that cannabinoid content could play a role in affecting blood pressure, with some previous studies showing that both CBD and THC both induce vasorelaxation and lower blood pressure.

This therapeutic potential of marijuana is making it possible for entities such as India Globalization Capital Inc. (NYSE American: IGC) to focus on developing THC-based formulations for conditions such as chronic pain, which take a toll on millions of Americans each year.

NOTE TO INVESTORS: The latest news and updates relating to India Globalization Capital Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Connecticut Lawmakers Consider Adding Marijuana DUI to Driving Curriculum

According to a recent bill discussed by the House’s Transportation Committee, Connecticut driver education courses would include information warning against the risks of driving while under the influence of marijuana. House Majority Leader Jason Rojas put forth the bill last month, and it had a public hearing last week. The proposed legislation would mandate that lessons on the risks of driving under the influence be included in private driver instruction courses as well as those provided at high schools and secondary schools.

The current law mandates that instruction on driving while impaired by drugs and alcohol be included in driver education, but it makes no explicit mention of cannabis. Proponents argue that it ought to be given recent state law revisions and widespread misconceptions about driving under the influence.

The bill comes after the state’s 2021 marijuana legalization law took effect and one month after commercial marijuana retailers began operating in Connecticut.

In his statement, Rojas stressed the need to take precautions to prevent minors from developing false beliefs about the effects of cannabis on their ability to drive. That misconception was further emphasized during the hearing by East Lyme Republican Rep. Holly Cheeseman, who has put forth similar legislation. According to Cheeseman, a lot of drivers don’t realize how using cannabis can affect their behavior behind the wheel.

There is a misconception that driving while high is safe, according to Cheeseman. “Oh, I’m a better driver because I drive more cautiously or slowly,” she said. “No. Let’s face it, if you’re driving 20 mph on Interstate 95, you’re just as dangerous as if you’re driving 80 mph because it impairs your depth perception and lane-change skills.”

Dr. Kevin Borrup, executive director of the Center for Injury Prevention at Connecticut Children’s Medical Center, claimed that cannabis use could slow or impair critical driving abilities like reaction times and coordination. Since marijuana is now legal for adult recreational use in Connecticut, Borrup argued that it is crucial for the state’s teen driver education program to cover the risks of driving under the influence of marijuana. “We are aware that young people in Connecticut and across the nation underestimate the dangers of operating a motor vehicle after consuming marijuana,” he said.

Christine Cohen, cochair of the Transportation Committee and a Guilford Democrat, stated that there has been an “alarming” rise in incidents of drunk driving. Cohen added that she believes that it is incumbent upon the committee — on the legislature — to address that.

As this industry grows in Connecticut, the stiff competition is likely to create a demand for alternative sources of funding, such as the products offered by REZYFi Inc., in order to enable enterprises to grow their product list and address the ever-increasing demands of consumers.

NOTE TO INVESTORS: The latest news and updates relating to REZYFi Inc. are available in the company’s newsroom at https://cnw.fm/REZY

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

Prime Harvest Inc. Reveals That Their Reg A+ Equity Offering Has Been Granted Approval to Go Ahead

  • Prime Harvest recently revealed that the company’s Reg A+ equity offering has been greenlighted by the SEC
  • The primary share offering will see the company market up to 10 million shares to investors at a price of $4.20 each, with estimated gross proceeds of $42 million
  • The company has said that net proceeds will be destined towards the acquisition of licensed assets, continued expansion of their delivery network and general corporate purposes

Prime Harvest, a technology-focused, full-service cannabis company based in San Diego, recently announced the qualification of its equity offering under the SEC’s Regulation A+. The offering, which has officially been qualified by the U.S. Security Exchange Commission (“SEC”) as of Jan. 25, 2023, will provide the company with authorization to commence marketing its upcoming equity placement to both, accredited and non-accredited investors via its online platform, www.Weed4ThePeople.com (https://cnw.fm/KcuMh).

Prime Harvest plans to raise gross proceeds of up to $42 million through its primary share issuance, a corporate action which will see the company offer up to 10,000,000 shares of common stock for sale at an initial public offer price of $4.20 per share. The company has announced that gross proceeds from the equity raising will be destined towards the acquisition of licensed assets, the development of Prime Harvest’s direct-to-consumer application, expansion of the company’s state-wide delivery capabilities, as well as general corporate purposes.

Dating back to the company’s change in corporate strategy in 2019, a move which saw Prime Harvest transition from its origins as one of San Diego County’s founding brick and mortar cannabis outlets towards a tech-focused retailer through its Jaxx Cannabis flagship retail and delivery platform, the company has seen its prospects rise to new highs. Boasting over 60+ brand partners, Prime Harvest has seen its revenues swell by upwards of 784% between 2019-2021, a function of the company seeing its unique customer numbers rise by over 212% during that interim, with the average consumer expending $75 on average per purchase.

More recently, Prime Harvest and its retail brand, Jaxx Cannabis, have taken the sale of cannabis to new technological heights through the creation and development of the Jaxx Delivery Mobile App. A reliable, sophisticated and easy to use platform, the Jaxx Delivery App aims to expand the company’s footprint to encompass much of California’s legal market – a bold and arduous move given the rising demand from previously unexploited submarkets within the Golden State.

Prime Harvest’s actions come at a pivotal time for the US cannabis market, with over 33 US states as well as the District of Columbia currently sanctioning the legal use of some form of cannabis. Consequently, the legal cannabis industry has rapidly become one of the fastest growing sectors of the US economy, with a recent study noting that the industry accounted for 250,000 jobs as of 2020 and would likely grow to a market size of $24.1 billion by 2025 (from $6.6 billion in 2016). One study in the meantime has opined that California alone could account for a remarkable $25 billion of a projected $50 billion nationwide market by 2026.

Despite predictions on market growth being wildly divergent on the back of varying levels of optimism surrounding the industry’s development prospects, Prime Harvest has sought to pre-emptively ensure that they will be able to capitalize on the sector’s ongoing evolution through its upcoming capital raising exercise as well as its market leading retail offer via Jaxx Cannabis.

For more information, visit the company’s website at www.PrimeHarvestInc.com.

NOTE TO INVESTORS: The latest news and updates relating to Prime Harvest are available in the company’s newsroom at https://cnw.fm/PRIME

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.